The FDA has approved the SetPoint System, a neuroimmune modulation device, for the treatment of adults with moderately to severely active rheumatoid arthritis.

The device stimulates the vagus nerve, signaling the body to tamp down the inflammation that contributes to the disease.

The agency’s decision was based on the outcomes of the double-blind, randomised, sham-controlled RESET-RA study.

The SetPoint System is an implanted device that stimulates the vagus nerve once a day. It was tested through a clinical trial at Northwell Health.

SetPoint Medical announced today that the FDA approved its SetPoint neuroimmune modulation system for treating rheumatoid ...

A first-of-its-kind implant has just been granted approval from the US Food and Drug Administration (FDA) for the treatment ...

SetPoint Medical's vagus nerve stimulator has received FDA approval for treating moderate-to-severe rheumatoid arthritis (RA) ...

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...

Setpoint, which is based in Austin and New York, launched a $31 million Series B round led by Andreessen Horowitz, a storied Silicon Valley investor that has backed giants such as Airbnb, Slack ...

NEW YORK--(BUSINESS WIRE)--Setpoint, the leading infrastructure provider for the credit industry, today announced the successful completion of its $31 million Series B funding round. 645 Ventures ...

The FDA has approved the SetPoint System, a vagus nerve stimulator from SetPoint Medical, for the treatment of rheumatoid arthritis.The device is an implantable, integrated neurostimulator about the ...

The FDA has approved a medical device that stimulates the vagus nerve for the treatment of moderate-to-severe rheumatoid ...